Target early and mid-stage companies, and invest in new drugs in bulk
Posted: Wed Jan 08, 2025 4:08 am
Lu Kongming said that the biotechnology industry is not affected by the boom, and even the worse the boom, the more money it makes from selling drugs. Therefore, Diamond Biotech aims to become a "biotech flagship creator" and hopes to incubate many biotech unicorns. "Diamond Investment This is a near-death industry, and you need a big heart to be in the biotech industry; you don’t seek stability, but you need explosive profits.”
Diamond Biotech Login
Since its establishment in 2013, Diamond Biotech has positioned itself as a sustainable venture capital investment company and currently invests in a total of 10 biotech companies.
Picture/Diamond Biotechnology
Diamond Biotechnology was initiated and established by Zhongtian Biotechnology Group. When the company was established, it combined the support of Fubon Financial Holdings, Taishin Financial Holdings and Runtai Group. Lu Kongming specially named four business leaders to thank them for their support from the early days until now. Including Fubon Media indonesia telegram Chairman Cai Mingzhong, Fubon Financial Holdings Chairman Cai Mingxing, Taishin Financial Holdings Chairman Wu Dongliang, and Runtai Group founder Yin Yanliang.
Diamond Biotechnology targets early- to mid-term internationally competitive investment targets around the world, with its main areas covering new drug research and development, high-end medical equipment, innovative medical service technologies or models, medical access, agricultural biotechnology, etc.
There are currently 10 biotechnology companies in the investment projects, with new drug investment accounting for 60%, medical equipment accounting for 20%, and others (cell therapy and agricultural biotechnology) accounting for 20%. Two of the companies, Integrated Biotechnology and Glycobiomedicine, have a market value of over one billion U.S. dollars and have been promoted to unicorns. Investments have entered a period of fruition and harvest. Xinyao Biomedical is about to be listed on the OTC market, and Immortal Cell and Ditiantai Agricultural Biotechnology will also have the opportunity to enter the capital market in the next year. In terms of overseas investment, Israel's EyeYon Medical is expected to obtain marketing authorization for artificial cornea from the US FDA in 2024.
Diamond Biotech Login
Since its establishment in 2013, Diamond Biotech has positioned itself as a sustainable venture capital investment company and currently invests in a total of 10 biotech companies.
Picture/Diamond Biotechnology
Diamond Biotechnology was initiated and established by Zhongtian Biotechnology Group. When the company was established, it combined the support of Fubon Financial Holdings, Taishin Financial Holdings and Runtai Group. Lu Kongming specially named four business leaders to thank them for their support from the early days until now. Including Fubon Media indonesia telegram Chairman Cai Mingzhong, Fubon Financial Holdings Chairman Cai Mingxing, Taishin Financial Holdings Chairman Wu Dongliang, and Runtai Group founder Yin Yanliang.
Diamond Biotechnology targets early- to mid-term internationally competitive investment targets around the world, with its main areas covering new drug research and development, high-end medical equipment, innovative medical service technologies or models, medical access, agricultural biotechnology, etc.
There are currently 10 biotechnology companies in the investment projects, with new drug investment accounting for 60%, medical equipment accounting for 20%, and others (cell therapy and agricultural biotechnology) accounting for 20%. Two of the companies, Integrated Biotechnology and Glycobiomedicine, have a market value of over one billion U.S. dollars and have been promoted to unicorns. Investments have entered a period of fruition and harvest. Xinyao Biomedical is about to be listed on the OTC market, and Immortal Cell and Ditiantai Agricultural Biotechnology will also have the opportunity to enter the capital market in the next year. In terms of overseas investment, Israel's EyeYon Medical is expected to obtain marketing authorization for artificial cornea from the US FDA in 2024.